Bristol Myers Squibb at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Bristol Myers Squibb exhibits at Booth 1313 at ASH 2026 in New Orleans. Its presence centres on myeloma and cell therapy, as it supports symposia on CAR T in myeloma and lymphoma, next options after myeloma relapse and protein-degrader drugs. It also supports symposia on MDS, myelofibrosis and community oncologists' questions about novel lymphoma therapies.
| Organization | ASH 2026 Attendance |
|---|---|
Bristol Myers Squibb Princeton, NJ | |
Global biopharmaceutical company with hematology medicines in myeloma, lymphoma, leukemia and anemia, including CAR T-cell therapies. | Booth Exhibiting at Booth 1313 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We’re Going Real patient cases showing how experts use approved and investigational CAR-T therapies in multiple myeloma now, and where the treatment is heading. Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. |
Instantly find 20 buyers from Bristol Myers Squibb
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction